A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MES-1022 IN HEALTHY HUMAN SUBJECTS
This is an early-stage research study, called a Phase 1 trial, where we are testing a new medicine known as MES-1022 for the very first time in people. The main goals are to check if the medicine is safe, how well the body tolerates it, and how it moves through and affects the body. We are looking for healthy adults to take part in this study. Participants will be randomly assigned to receive either the new medicine or a placebo (a dummy treatment). This type of study is crucial for understanding new medicines, especially those that might eventually help people with metabolic bone diseases, which are conditions that affect the strength and health of your bones.
At a glance
What is this study about?
This study is a very early step in developing a new medicine called MES-1022. It’s what we call a ‘Phase 1’ study, which means it’s the very first time this particular medicine is being given to people. The main purpose at this stage is not to treat a specific illness, but to understand if the medicine is safe, how well people tolerate it, and how it behaves inside the body. Think of it like a thorough safety check on a brand new car model before it goes out for general use.
We’re giving MES-1022 to healthy adult volunteers so we can carefully watch for any side effects and learn how the body processes the medicine. This involves seeing how much medicine gets into the bloodstream, how long it stays there, and what effects it might have. Some participants will receive a single dose, while others might receive several doses over a period, with careful increases in the amount given. This helps us find the right dose that is both safe and effective.
The findings from this study are really important because they will help researchers decide if MES-1022 is promising enough to continue testing in later stages with people who have metabolic bone diseases. These diseases affect your bones, making them weak or brittle, and can lead to problems like osteoporosis.
Key takeaways
- This is a key first safety study for a new medicine.
- It's looking at MES-1022 for bone conditions, but participants are healthy.
- You might get the new medicine or a dummy treatment (placebo).
- Participation involves clinic visits, blood tests, and close monitoring.
- Your health and safety are the top priority throughout the study.
Who may be eligible?
To be considered for this study, you need to be a healthy adult aged 18 or older. Both men and women are welcome to take part.
Because this is a study looking at how a new medicine affects healthy people, there will be specific health checks to make sure you don't have any underlying medical conditions that could make taking the medicine risky or affect the study results. This includes checking your general health, blood tests, and other medical assessments.
The research team will review your medical history and perform some tests to confirm you meet all the health requirements. They will explain exactly what conditions or medications might prevent you from joining, but generally, the aim is to find people in good overall health.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you consider yourself generally healthy?
- Are you available for multiple clinic visits?
- Are you comfortable with blood tests and other medical checks?
What does participation involve?
If you decide to take part in this study, you will first go through a screening process, which involves medical checks and tests, to make sure you are suitable. Once confirmed, you will be randomly assigned to receive either the new medicine MES-1022 or a placebo (a dummy treatment that looks just like the medicine but has no active ingredient). Neither you nor the study team will know which you are receiving.
Your participation will involve several visits to the study clinic. These visits will include taking the study medication, having regular blood samples taken, providing urine samples, and undergoing various medical checks like measuring your heart rate, blood pressure, and overall health assessments. Depending on whether you receive a single dose or multiple doses, you might stay at the clinic for a short period. There will also be follow-up appointments to monitor your health after you've taken the study medication. The exact number of visits and the total time involved will be explained clearly by the study team, but typically, these early-stage studies can last several weeks from your first screening appointment to your final follow-up.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is a Phase 1 study?
A Phase 1 study is the first time a new medicine is tested in people. Its main goal is to check if the medicine is safe and how the body handles it, not to treat a disease.
What are metabolic bone diseases?
These are conditions that affect the strength and health of your bones, like osteoporosis, which can make bones weak and easily broken.
Will I definitely receive the new medicine?
No, you might receive the new medicine (MES-1022) or a placebo (a dummy treatment). This is decided randomly, and neither you nor the doctors will know which you are getting.
Will I be paid for taking part?
The study information will explain if there is any reimbursement for your time, travel, or expenses. This is common in some healthy volunteer studies.
Can I stop participating if I change my mind?
Yes, you have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.